497 related articles for article (PubMed ID: 19188319)
41. Accuracy of fluorodeoxyglucose-positron emission tomography for diagnosis of single bone metastasis: comparison with bone scintigraphy.
Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
J Comput Assist Tomogr; 2007; 31(5):812-9. PubMed ID: 17895798
[TBL] [Abstract][Full Text] [Related]
42. Histogram analysis for characterization of indeterminate adrenal nodules on noncontrast CT.
Lin MF; Chang-Sen LQ; Heiken JP; Pilgram TK; Bae KT
Abdom Imaging; 2015 Aug; 40(6):1666-74. PubMed ID: 25488345
[TBL] [Abstract][Full Text] [Related]
43. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules.
Ohno Y; Koyama H; Takenaka D; Nogami M; Maniwa Y; Nishimura Y; Ohbayashi C; Sugimura K
J Magn Reson Imaging; 2008 Jun; 27(6):1284-95. PubMed ID: 18504748
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic performance of PET/CT in differentiation of malignant and benign non-solid solitary pulmonary nodules.
Tsushima Y; Tateishi U; Uno H; Takeuchi M; Terauchi T; Goya T; Kim EE
Ann Nucl Med; 2008 Aug; 22(7):571-7. PubMed ID: 18756359
[TBL] [Abstract][Full Text] [Related]
45. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
Lu Y; Xie D; Huang W; Gong H; Yu J
Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976
[TBL] [Abstract][Full Text] [Related]
46. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
[TBL] [Abstract][Full Text] [Related]
47. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET.
Hickeson M; Yun M; Matthies A; Zhuang H; Adam LE; Lacorte L; Alavi A
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1639-47. PubMed ID: 12458399
[TBL] [Abstract][Full Text] [Related]
48. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
49. Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology.
Karam M; Roberts-Klein S; Shet N; Chang J; Feustel P
J Nucl Med; 2008 Sep; 49(9):1429-36. PubMed ID: 18765585
[TBL] [Abstract][Full Text] [Related]
50. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
[TBL] [Abstract][Full Text] [Related]
51. Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET?
Tochetto SM; Rezai P; Rezvani M; Nikolaidis P; Berggruen S; Atassi B; Salem R; Yaghmai V
Radiology; 2010 Apr; 255(1):164-72. PubMed ID: 20308454
[TBL] [Abstract][Full Text] [Related]
52. Computer-aided detection (CAD) and assessment of malignant lesions in the liver and lung using a novel PET/CT software tool: initial results.
Hahn S; Heusner T; Zhou X; Zhan Y; Peng Z; Hamami M; Forsting M; Bockisch A; Antoch G
Rofo; 2010 Mar; 182(3):243-7. PubMed ID: 19859858
[TBL] [Abstract][Full Text] [Related]
53. FDG-PET/CT for diagnosis of primary ovarian cancer.
Kitajima K; Suzuki K; Senda M; Kita M; Nakamoto Y; Onishi Y; Maeda T; Yoshikawa T; Ohno Y; Sugimura K
Nucl Med Commun; 2011 Jul; 32(7):549-53. PubMed ID: 21407140
[TBL] [Abstract][Full Text] [Related]
54. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
55. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
56. Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules.
Higashi K; Ueda Y; Sakuma T; Seki H; Oguchi M; Taniguchi M; Taki S; Tonami H; Katsuda S; Yamamoto I
J Nucl Med; 2001 Oct; 42(10):1489-96. PubMed ID: 11585862
[TBL] [Abstract][Full Text] [Related]
57. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA
Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980
[TBL] [Abstract][Full Text] [Related]
58. (18)F-FDG PET-CT respiratory gating in characterization of pulmonary lesions: approximation towards clinical indications.
García Vicente AM; Soriano Castrejón AM; Talavera Rubio MP; León Martín AA; Palomar Muñoz AM; Pilkington Woll JP; Poblete García VM
Ann Nucl Med; 2010 Apr; 24(3):207-14. PubMed ID: 20177834
[TBL] [Abstract][Full Text] [Related]
59. Differentiation of an adrenal mass in patients with non-small cell lung cancer by means of a normal range of adrenal standardized uptake values on FDG PET/CT.
Kim BS; Lee JD; Kang WJ
Ann Nucl Med; 2015 Apr; 29(3):276-83. PubMed ID: 25480483
[TBL] [Abstract][Full Text] [Related]
60. Accuracy of FDG PET/CT in the evaluation of solitary pulmonary lesions - own experience.
Opoka L; Kunikowska J; Podgajny Z; Szołkowska M; Błasińska-Przerwa K; Burakowska B; Oniszh K; Rudziński P; Bestry I; Roszkowski-Śliż K
Pneumonol Alergol Pol; 2014; 82(3):198-205. PubMed ID: 24793147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
